Only logged in customers who have purchased this product may leave a review.
ACE-031 1mg
Research Grade Peptide
- Research Grade
- 99% Purity
- Third-Party Verified
Reference Strength: 1mg
R799,00
CAS: Not assigned
Formula: ~110 kDa
Molecular Weight: ~110 kDa
Chemical Name / Amino Acid Sequence: Proprietary fusion protein
Availability: In stock
SKU: AE1
ACE-031 1mg
R799,00
ACE-031 is a recombinant ActRIIB-Fc fusion protein investigated for its ability to inhibit myostatin and related TGF-β ligands that regulate skeletal muscle growth. It has been studied in preclinical models and early human clinical trials for its potential effects on lean body mass, muscle strength and body composition.
Availability: In stock
Included with your purchase
Each qualifying product includes 3ml of 0.9% Benzyl Alcohol Bacteriostatic Water.
Complimentary Purchase Kit
Every qualifying vial includes a complimentary purchase kit at no additional cost.
Research Overview
About ACE-031 1mg
ACE-031 is a soluble activin receptor type IIB (ActRIIB) fusion protein that acts as a ligand trap. Rather than stimulating muscle growth directly, it binds circulating proteins such as myostatin and activins before they reach their cellular receptors. Researchers have investigated this mechanism as a potential strategy for increasing skeletal muscle mass in conditions associated with muscle wasting. Although early studies demonstrated increases in lean body mass, clinical development was discontinued following vascular-related adverse events.
How It Works in Research
ACE-031 functions as a soluble decoy receptor derived from activin receptor type IIB. Once administered, it binds myostatin, activin A, GDF-11 and several related ligands belonging to the transforming growth factor-beta (TGF-β) superfamily. These proteins normally suppress muscle growth by activating ActRIIB receptors on skeletal muscle cells. By preventing this interaction, ACE-031 reduces inhibitory signalling and allows researchers to investigate increased muscle protein synthesis, muscle fibre growth and improvements in lean body mass. Unlike anabolic steroids, ACE-031 does not activate androgen receptors, and unlike growth hormone secretagogues it does not rely on the GH/IGF-1 axis. Instead it targets one of the body's primary regulators of muscle growth. Early clinical studies demonstrated measurable increases in lean body mass, but development was halted after vascular-related adverse events were observed, meaning long-term efficacy and safety remain uncertain.
Research Applications
• Muscle hypertrophy • Sarcopenia • Muscular dystrophy • Cachexia • Rehabilitation research • Body composition
ACE-031 is researched because it blocks proteins that naturally limit muscle growth. By reducing these inhibitory signals, researchers investigate whether muscles can grow larger and stronger.
Product Specifications
- Product Name: ACE-031
- Alternate Chemical Name: ActRIIB-Fc Fusion Protein
- Product Type: Recombinant Fusion Protein
- CAS Number: Not assigned
- Molecular Formula: Proprietary biologic
- Molecular Weight: ~110 kDa
Research Information
- Amino Acid Sequence: Proprietary fusion protein
- Reference Strength: 1 mg
- Appearance: White to off-white lyophilised powder
- Purity Standard: ≥98% (HPLC)
- Category: Myostatin / Activin Inhibitor
- Storage: 2–8°C after reconstitution
Mechanism of Action
ACE-031 functions as a soluble decoy receptor derived from activin receptor type IIB. Once administered, it binds myostatin, activin A, GDF-11 and several related ligands belonging to the transforming growth factor-beta (TGF-β) superfamily. These proteins normally suppress muscle growth by activating ActRIIB receptors on skeletal muscle cells. By preventing this interaction, ACE-031 reduces inhibitory signalling and allows researchers to investigate increased muscle protein synthesis, muscle fibre growth and improvements in lean body mass.
Key Research Characteristics
Recombinant ActRIIB-Fc fusion protein
Myostatin/Activin pathway inhibitor Long-acting biologic Investigated in muscle wasting disorders Early clinical and extensive preclinical research
Potential Benefits in Research
Preclinical and early clinical studies investigated ACE-031 for increasing lean body mass, improving muscle strength, enhancing recovery from muscle wasting conditions and improving overall body composition. Researchers also explored its use in Duchenne muscular dystrophy and other neuromuscular disorders where preservation of muscle mass may be beneficial. These findings remain investigational and should not be interpreted as established therapeutic outcomes.
Safety Profile
Early human studies reported epistaxis (nosebleeds), telangiectasia (small dilated blood vessels), headache and mild injection-site reactions. These vascular findings contributed to discontinuation of clinical development. Long-term human safety is unknown because larger clinical trials were not completed.
Research Applications
Muscle hypertrophy
Sarcopenia
Muscular dystrophy
Cachexia
Rehabilitation research
Body composition
Weight-based and concentration tables are research references and not established clinical dosing recommendations.
REFERENCE RECONSTITUTION INFORMATION
Evidence Status: Early clinical and preclinical research. Mechanism: Myostatin and activin ligand trap. Reconstitution: Add 2.0 mL bacteriostatic water to one 1 mg vial to produce a concentration of 0.5 mg/mL. Published studies used weight-based investigational dosing rather than fixed-dose research vials.
Always follow sterile preparation techniques when handling research peptides.
⚠️ DISCLAIMER: This guide is for educational purposes only and is not medical advice. For research use only.
General Preparation
• Use a new sterile syringe for each preparation. • Rotate injection sites if applicable to the research protocol. • Store refrigerated after reconstitution. • Record preparation date and storage conditions. • Weight-based and concentration tables are research references and not established clinical dosing recommendations.
- Using a sterile syringe, slowly add 2.0 mL bacteriostatic water down the inside wall of the vial. Allow the powder to dissolve naturally, then gently swirl until the solution is clear. Do not shake vigorously. Refrigerate immediately after reconstitution.
ACE-031 (1MG)- RECONSTITUTION TABLES
Reference Handling Information
Reference information for laboratory handling of ACE-031 1mg.
- No universally accepted dosing protocol exists for commercially available 1 mg ACE-031 research vials. Published clinical studies used weight-based dosing under controlled research conditions.
Reference Parameters (Concentration Reference)
| Dose (mg) | Volume | U-100 Units |
|---|---|---|
| 0.10 | 0.20 mL | 20 |
| 0.20 | 0.40 mL | 40 |
| 0.25 | 0.50 mL | 50 |
| 0.50 | 1.00 mL | 100 |
For laboratory research only.
Reference Parameters (Weight-Based Research Reference)
| Body Weight | Low 0.02 mg/kg | Mid 0.10 mg/kg | High 0.20 mg/kg |
|---|---|---|---|
| 50 kg | 1.0 mg | 5.0 mg | 10.0 mg |
| 60 kg | 1.2 mg | 6.0 mg | 12.0 mg |
| 70 kg | 1.4 mg | 7.0 mg | 14.0 mg |
| 80 kg | 1.6 mg | 8.0 mg | 16.0 mg |
| 90 kg | 1.8 mg | 9.0 mg | 18.0 mg |
| 100 kg | 2.0 mg | 10.0 mg | 20.0 mg |
For laboratory research only.
View Certificate of Analysis
View Certificate of Analysis Each batch of ACE-031 is independently tested by third-party laboratories. Download the Certificate of Analysis to verify purity, identity, and quality.
99.6%
Verified Purity
3rd Party
Lab Tested
Certified
Quality Assured
Related products
-
Tissue Repair & Recovery Research
BPC-157
Price range: R450,00 through R599,00 Select options This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.
Only logged in customers who have purchased this product may leave a review.
PURE PERFORMANCE LABS
Recommended Research Products
Explore related compounds commonly viewed alongside this product.
FOR RESEARCH PURPOSES ONLY
This product is intended for research and laboratory use only. Always consult qualified researchers and follow appropriate safety protocols.
Reviews
There are no reviews yet.